Juno Therapeutics, which is developing immunotherapy treatments for hematologic and solid tumor cancers, filed on Monday with the SEC to raise up to $150 million in an initial public offering.
The year's largest biotechs by deal size (FWP; $221 million) and market cap (FGEN; $1.2 billion) have gone public in the fourth quarter, and Juno's $150 million proposed deal size would make it the year's second largest biotech IPO.
Other immunotherapy-based cancer biotechs to IPO in 2014 include Kite Pharma (KITE), Immune Design (IMDZ) and Affmided Therapeutics (AFMD).
The Seattle, WA-based company, which was founded in 2013, plans to list on the NASDAQ under the symbol JUNO. Juno Therapeutics initially filed confidentially on September 12, 2014. Morgan Stanley, J.P. Morgan and Goldman Sachs are the joint bookrunners on the deal. No pricing terms were disclosed.
